SCHEMBL16808462

SCHEMBL16808462

COC(=O)[C@H]1OC(c2ccccc2)O[C@@H]1c1ccccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.40
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
GLA P06280 4/20 0.40
GAA P10253 4/20 0.40
HPGD P15428 2/20 0.40
CASP1 P29466 2/20 0.40
CASP7 P55210 2/20 0.40
HSD17B10 Q99714 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
MAPK1 P28482 1/20 0.39
POLB P06746 1/20 0.39
BACE1 P56817 1/20 0.38
CYP2D6 P10635 2/20 0.38
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
MAPT P10636 1/20 0.37
ITGA4 P13612 1/20 0.37
FABP5 Q01469 1/20 0.36
SIRT1 Q96EB6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16808388 1.00 TSHR (0.40) TSHRALDH1A1KDM4EGLAGAA
SCHEMBL18801893 1.00 TSHR (0.40) TSHRALDH1A1KDM4EGLAGAA
SCHEMBL27085617 1.00 TSHR (0.40) TSHRALDH1A1KDM4EGLAGAA
SCHEMBL27085629 1.00 TSHR (0.40) TSHRALDH1A1KDM4EGLAGAA
SCHEMBL16808479 0.87 PDE5A (0.41) TSHRALDH1A1KDM4EGAAHPGD
SCHEMBL18801834 0.87 PDE5A (0.41) TSHRALDH1A1KDM4EGAAHPGD
SCHEMBL16808486 0.87 PDE5A (0.41) TSHRALDH1A1KDM4EGAAHPGD
SCHEMBL9692787 0.87 ALDH1A1 (0.47) TSHRALDH1A1KDM4EGLAGAA
SCHEMBL18186731 0.85 TSHR (0.44) TSHRALDH1A1KDM4EGAAHPGD
SCHEMBL28364992 0.85 TSHR (0.44) TSHRALDH1A1KDM4EGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-02-13 US disclosed
EP-4211125-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-19 EP disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
WO-2022054987-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-03-17 WO disclosed
US-9937145-B2 Sulfamate derivative compound for use in preventing or treating epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-04-10 US disclosed
US-9937145-B2 Sulfamate derivative compound for use in preventing or treating epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-04-10 US disclosed
US-9834535-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2017-12-05 US disclosed
US-9834535-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2017-12-05 US disclosed
EP-2861571-B1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO LTD (KR) 2017-05-03 EP disclosed
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-03 US disclosed
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
WO-2015088273-A9 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-08-06 WO disclosed
WO-2015088271-A1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed
WO-2015088273-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain SULT2A1, STS, SULT1A1 TSHR 4413/4885ALDH1A1 920/4885KDM4E 2012/4885
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER SLC6A4, SLC6A3, SLC6A2 TSHR 2322/4885ALDH1A1 776/4885KDM4E 926/4885
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME MYLK, MUSK, MYLK2 TSHR 2872/4885ALDH1A1 3249/4885KDM4E 664/4885
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy STS, SULT2A1, GRIK5 TSHR 4659/4885ALDH1A1 649/4885KDM4E 479/4885
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder SLC6A4, SLC6A3, SLC6A2 TSHR 2322/4885ALDH1A1 776/4885KDM4E 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.